Insmed discontinues development of skin condition drug
07/04/2026 21:06
April 7 (Reuters) - Insmed INSM.O said on Friday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Shreya Biswas) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Insmed Incorporated
See all newsBrief: Insmed Launches Brinsupri® Tablets 25 Mg (Brensocatib Hydrate) For The Treatment Of Non-Cystic Fibrosis Bronchiectasis In Japan
Brief: Insmed Incorporated - Launches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases
U.S. STOCKS ON THE MOVE-Nike, Synopsys, Intel
Insmed CFO Sara Bonstein steps down; shares fall
U.S. STOCKS ON THE MOVE- Cenovus Energy, TeraWulf, Alector